Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced a live webcast and conference call scheduled for 8:30 a.m. ET on March 22, 2023, to discuss its fourth quarter and full year 2022 financial results, along with a business update. Analysts can participate in a Q&A session during the call. The call will be accessible through the investor relations section of their website. Additionally, an archived version of the webcast will be available afterward. Wave Life Sciences focuses on developing genetic medicines using its proprietary PRISM platform, targeting a range of genetically defined diseases.

Positive

• Scheduled Q4 and FY 2022 financial results call on March 22, 2023, indicating transparency and engagement with investors.

Negative

• None.

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com/events-and-presentations.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
InvestorRelations@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

When will Wave Life Sciences announce its Q4 and FY 2022 financial results?

Wave Life Sciences will announce its Q4 and FY 2022 financial results on March 22, 2023, at 8:30 a.m. ET.

How can investors access the Wave Life Sciences conference call?

Investors can access the conference call through the investor relations section of the Wave Life Sciences website.

Is there a Q&A session during the Wave Life Sciences call?

Yes, there will be a Q&A session available for analysts during the Wave Life Sciences conference call.

What is the focus of Wave Life Sciences?

Wave Life Sciences focuses on developing life-changing genetic medicines for genetically defined diseases using the PRISM platform.